We are developing Norbinal as a potential candidate medication for sustained and consistent therapeutic effects, improved outcomes, and patient satisfaction in a broad spectrum of neuropsychiatric conditions including ADHD, Major Depressive Disorder and Fragile X syndrome.
Norbinal is a selective kappa opioid receptor (KOR) antagonist and belongs to a novel class of medications being investigated for the treatment of various CNS disorders. Norbinal distinguishes itself from other kappa opioid receptor antagonists in laboratory tests by its prolonged duration of action, which allows for less frequent dosing and potentially better patient adherence to treatment regimens.
A non-stimulant, non-addictive, next generation candidate medication with excellent benefits and fewer stimulant associated side effects in non-clinical laboratory tests.
Despite the FDA's approval of several non-stimulant medications for ADHDover the past few decades, psycho stimulants remain the prescribers’ predominant choice, accounting for nearly 90% of all ADHD prescriptions. Why? Because none of the currently approved non-stimulant medications has shown adequate efficacy or substantial improvements in safety and tolerability to replace stimulants as the primary treatment option.
Norbinal seeks to distinguish itself by becoming a superior treatment option for ADHD patients and prescribers seeking safe and effective therapies. Upon receiving regulatory approvals, Norbinal has the potential to shift the ADHD market landscape by changing prescription practices, and potentially reducing the reliance on traditional stimulant medications for ADHD.
Fragile X syndrome is a genetic condition characterized by intellectual disability, behavioral and learning challenges. It is the most common inherited cause of intellectual disability and autism spectrum disorder.Fragile X syndrome is caused by a mutation in the FMR1 gene, which leads to a deficiency in a protein essential for brain development and function. There is currently no cure for the condition.
Norbinal has shown excellent potential in laboratory tests in genetic model systems as a non-stimulant, non-addictive, next generation medication for the treatment of Fragile X Syndrome.
Major depressive disorder (MDD),often simply referred to as depression, is a common and serious mood disorder.It causes severe symptoms that affect how an individual feels, thinks, and handles daily activities, such as sleeping, eating, or working. MDD is characterized by persistent feelings of sadness, hopelessness, or loss of interest in activities once enjoyed. It can also lead to various emotional and physical problems and can decrease a person's ability to function at work and at home. Treatment for MDD typically includes a combination of psychotherapy and medication, such as antidepressants.
The kappa opioid receptor (KOR)is involved in regulating mood and stress responses in the brain. By blocking this receptor, Norbinal has the potential to produce antidepressant effects, potentially offering a new approach to treating depression. Clinical trials are ongoing to evaluate the safety and efficacy of kappa opioid receptor antagonists for depression, and early results are promising.
Norbinal distinguishes itself from other KOR antagonists in laboratory tests by its prolonged duration of action, which allows for less frequent dosing and potentially better patient adherence to treatment regimens. It can be particularly beneficial in the treatment of depression, where long-term therapy is often necessary to minimize fluctuations in mood and improve overall symptom control.
Overall, Norbinal has the potential to be a breakthrough kappa receptor antagonist by providing sustained and consistent therapeutic effects, leading to improved outcomes and patient satisfaction in the treatment of depression and other conditions.